Clinical oncology pharmacist Amy Indorf, PharmD, BCOP, discusses her presentation on the role of PARP inhibitors for ovarian cancer.
Angiogenesis inhibitors inhibit the activity of vascular endothelial growth factor (VEGF), a protein that stimulates angiogenesis. The angiogenesis inhibitor used to treat ovarian cancer is: Bevacizumab (Avastin) PARP inhibitors: PARP inhibitors are used as maintenance therapy for ovarian cancer in ...
In recent years, more and more novel PARP-1 inhibitors have been reported. This review has attempted to summarize the structural types and characteristics of various novel PARP-1 inhibitors reported since 2020. And we outlined the current clinical application potential of PARP-1 inhibitors and ...
When the cells were treated with this dendrimer, a decrease in the protein levels of active caspase-3 and proteolytically cleaved PARP was remarkably observed. Since cytochrome c release from the mitochondria to the cytoplasm was unaffected in the presence of dendrimer 2a, the observed suppressive ...
Poly(ADP-ribose)polymerase (PARP) inhibitors decrease angiogenesis through reducing vascular endothelium growth factor (VEGF) induced proliferation, migrat... H Chen,W Jia,X Xu,... - 《Biochemical & Biophysical Research Communications》 被引量: 59发表: 2008年 Effects of Homocysteine and Ginsenoside...
Elacestrant(Orserdu)andfulvestrant(Faslodex) are selective estrogen receptor degraders (SERDs). These medications work by blocking and damaging estrogen receptors and are sometimes used in the treatment of metastatic breast cancer. A class of medicines called aromatase inhibitors actually stops estrogen...
T-cell lymphomas are rare and aggressive malignancies associated with poor outcome, often because of the development of resistance in the lymphoma against
All showed some level of apoptotic cell death, which was confirmed by detection of PARP cleavage. Sensitivity to the drugs varied among cell lines, ranging from 20% to 90% apoptosis after treatment. Our data suggest that 17-DMAG may be more potent than 17-AAG. HSP90 inhibitors are ...
Cancer cells displaying HR deficiency (HRD) are selectively eliminated by poly(ADP-ribose) polymerase inhibitors (PARPis). To date, sequencing of HR-associated genes and analyzing genome instability have been used as clinical predictions for PARPi therapy. However, these genetic tests cannot reflect...
activation of metalloproteinase 11/stromelysin-3 and up-regulation of Crx and CoREST, followed by the down-modulation of cone-specific phototransduction genes, transient up-regulation of regulatory/survival genes and activation of caspase-7 without apoptosis. Conversely, PARP1+-apoptotic rods develop ...